Gil Beyen, Erytech CEO
June 13, 2023 07:31 AM EDTUpdated 12:28 PM
People
Deals

Ery­tech blasts ac­tivist in­vestor's at­tempt to block re­verse merg­er, Akka­di­an pro­pos­es new board in re­turn

Amber Tong

Ery­tech is duk­ing it out with an ac­tivist in­vestor fierce­ly op­posed to its pro­posed merg­er with fel­low French biotech Phere­cy­des. Af­ter the com­pa­ny fired back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times